Day One Biopharmaceuticals’ (DAWN) “Buy” Rating Reiterated at Needham & Company LLC
Day One Biopharmaceuticals (NASDAQ:DAWN – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Monday,Benzinga reports. They currently have a $33.00 price objective on the stock. Needham & Company LLC’s price target indicates a potential upside of […]
More Stories
Cadent Capital Advisors LLC Increases Holdings in Fidelity Total Bond ETF (NYSEARCA:FBND)
Cadent Capital Advisors LLC increased its position in Fidelity Total Bond ETF (NYSEARCA:FBND – Free Report) by 13.4% in the...
Bridge Creek Capital Management LLC Cuts Stock Holdings in Colgate-Palmolive (NYSE:CL)
Bridge Creek Capital Management LLC cut its holdings in shares of Colgate-Palmolive (NYSE:CL – Free Report) by 0.2% during the...
CHICAGO TRUST Co NA Purchases 1,299 Shares of RTX Co. (NYSE:RTX)
CHICAGO TRUST Co NA raised its position in RTX Co. (NYSE:RTX – Free Report) by 11.2% during the 4th quarter,...
Moody National Bank Trust Division Sells 380 Shares of Marathon Petroleum Co. (NYSE:MPC)
Moody National Bank Trust Division decreased its position in Marathon Petroleum Co. (NYSE:MPC – Free Report) by 2.6% during the...
CHICAGO TRUST Co NA Increases Stake in QUALCOMM Incorporated (NASDAQ:QCOM)
CHICAGO TRUST Co NA raised its stake in shares of QUALCOMM Incorporated (NASDAQ:QCOM – Free Report) by 12.6% during the...
CV Sciences (OTCMKTS:CVSI) and Blueprint Medicines (NASDAQ:BPMC) Head-To-Head Survey
CV Sciences (OTCMKTS:CVSI – Get Free Report) and Blueprint Medicines (NASDAQ:BPMC – Get Free Report) are both medical companies, but...